An analysis of variability in the manufacturing of dexosomes: Implications for development of an autologous therapy

Biotechnology and Bioengineering

Volumn 92, Issue 2, 2005, Pages 238-249

  Patel, Sanjay ^a   Mehta Damani, Anita ^a   Shu, Helen ^a   Le Pecq, Jean Bernard ^a  

^a Anosys Inc   (United States)

Author keywords

Autologous therapy; Cancer vaccine; Dexosomes; Exosomes; Process analysis; Process variability

Indexed keywords

ANTIGENS; CELLS; DRUG THERAPY; TUMORS;

CANCER VACCINE; DEXOSOMES; EXOSOMES; PROCESS ANALYSIS; PROCESS VARIABILITY;

CHROMOSOMES;

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NANOPARTICLE; MHC CLASS II TRANSACTIVATOR PROTEIN; NUCLEAR PROTEIN; TRANSACTIVATOR PROTEIN;

ANALYTIC METHOD; ANALYTICAL PARAMETERS; ARTICLE; AUTOLOGOUS THERAPY; CANCER PATIENT; CELL VACUOLE; CLINICAL ARTICLE; COMPUTER SIMULATION; CONTROLLED STUDY; DEXOSOME; DONOR; HUMAN; IMMUNOTHERAPY; LARGE SCALE PRODUCTION; MEASUREMENT; MODEL; QUANTITATIVE ANALYSIS; ANALYSIS OF VARIANCE; BIOLOGICAL THERAPY; CELL CULTURE; CULTURE TECHNIQUE; DENDRITIC CELL; EVALUATION; HEALTH CARE QUALITY; LUNG TUMOR; MELANOMA; METABOLISM; METHODOLOGY; MONONUCLEAR CELL; SENSITIVITY AND SPECIFICITY; TRANSPORT VESICLE; ULTRASTRUCTURE;

ANALYSIS OF VARIANCE; CELL CULTURE TECHNIQUES; CELLS, CULTURED; DENDRITIC CELLS; HUMANS; LEUKOCYTES, MONONUCLEAR; LUNG NEOPLASMS; MELANOMA; NUCLEAR PROTEINS; QUALITY ASSURANCE, HEALTH CARE; SENSITIVITY AND SPECIFICITY; TISSUE THERAPY; TRANS-ACTIVATORS; TRANSPORT VESICLES;

EID: 21244465706     PISSN: 00063592     EISSN: None     Source Type: Journal    
DOI: 10.1002/bit.20596     Document Type: Article

References (16)

1. Cella M, Engering A, Pinet V, Pieters J, Lanzavecchia A. 1997. Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells. Nature 388:782-787.
2. Chaput N, Schartz NE, Andre F, Taieb J, Novault S, Bonnaventure P, Aubert N, Bernard J, Lemonnier F, Merad M, Adema G, Adams M, Ferrantini M, Carpentier AF, Escudier B, Tursz T, Angevin E, Zitvogel X. 2004. Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol 172:2137-2146.
3. Denzer K, Kleijmeer MJ, Heijnen HF, Stoorvogel W, Geuze HJ. 2000. Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 113:3365-3374.
4. Devore JL. 2000. Probability and statistics for engineering and the sciences. Pacific Grove, USA: Duxbury Press.
5. Escudier B, Dorval T, Chaput N, Novault S, Caby MP, Flament C, Andre F, Leboulaire C, Borg C, Amigorena S, Boccaccio C, Bonnerot C, Dhellin O, Movassagh M, Piperno S, Robert C, Serra V, Valente N, LePecq JB, Spatz A, Lantz O, Tursz T, Angevin E, Zitvogel L. 2005. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived exosomes: Results of the first phase I clinical trial. J Transl Med 3:10.
6. Evans M, Hasting M, Peacock B. 2000. Statistical distributions. New York, NY: John Wiley. p 230.
7. Fevrier B, Raposo G. 2004. Exosomes: Endosomal-derived vesicles shipping extracellular messages. Curr Opin Cell Biol 16:415-421.
8. Hsu DH, Paz P, Villaflor G, Rivas A, Mehta-Damani A, Angevin E, Zitvogel L, Le Pecq JB. 2003. Exosomes as a tumor vaccine: Enhancing potency through direct loading of antigenic peptides. J Immunother 26:440-450.
9. Hugel B, Martinez MC, Kunzelmann C, Freyssinet JM. 2005. Membrane microparticles: Two sides of the coin. Physiology (Bethesda) 20:22-27.
10. Lamparski HG, Metha-Damani A, Yao JY, Patel S, Hsu DH, Ruegg C, Le Pecq JB. 2002. Production and characterization of clinical grade exosomes derived from dendritic cells. J Immunol Methods 270:211-226.
11. Laulagnier K, Motta C, Hamdi S, Roy S, Fauvelle F, Pageaux JF, Kobayashi T, Salles JP, Perret B, Bonnerot C, Record M. 2004. Mast cell- and dendritic cell-derived exosomes display a specific lipid composition and an unusual membrane organization. Biochem J 380:161-171.
12. Lee TL, Wang JW. 2003. Statistical methods for survival data analysis. Hoboken, NJ: John Wiley & sons, p 513.
13. Morse MA, Garst J, Osada T, Khan S, Hobeika A, Clay TM, Valente N, Shreeniwas R, Sutton MA, Delcayre A, Hsu DH, Le Pecq JB, Lyerly HK. 2005. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med 3:9.
14. Royston P. 1995. A remark of algorithm AS 181: The W test for normality applied. Statistics 44:547-551.
15. Théry C, Zitvogel Z, Amigorena S. 2002. Exosomes: Composition, biogenesis and function. Nat Rev Immunol 2:569-579.
16. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, Ricciardi-Castagnoli P, Raposo G, Amigorena S. 1998. Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell-derived exosomes. Nat Med 4:594-600.